Trial
NCT00266357
Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
H. Lundbeck A/S
Collaborators
—
Condition
Primary Insomnia
Intervention
MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-01-14